Updated results from a phase II trial of Reolysin and paclitaxel in ovarian cancer patients showed that an intent-to-treat analysis of tumor response, as assessed by CA-125 antigen levels, demonstrated statistically significantly higher full response rates and stable disease or better rates in the test arm compared to paclitaxel alone.
Citius Oncology announced positive topline results from a completed investigatorāinitiated phaseāÆI clinical trial conducted by University of Pittsburgh investigators. This study evaluated the direct T-regulatory cell depletion activity of Lymphir (denileukin diftitoxācxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (Keytruda) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies.
